Kevin D Eng of the $2 billion Colombus Hill Management fund has made some intriguing shifts in his Q1 portfolio including boosting his …
Valeant Pharmaceuticals Intl Inc’s (NYSE:VRX) Branded Rx division has been making headlines as the embattled drugmaker struggles to prevent generic competition from eroding …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) wholly owned subsidiary, Bausch + Lomb, announced the launch of renu® Advanced Formula multi-purpose solution for soft and …
Hedge fund manager Chris Davis once said the key to understanding how to invest wisely is to not fall prey to buzz, realizing …
Hedge fund guru Richard Chilton is the face behind Chilton Investment Company, the man who took his B.S.
In the biotech-verse, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is riding a fresh wave of positive momentum following first quarter earnings that outclassed investors’ …
Valeant Pharmaceuticals Intl Inc’s (NYSE:VRX) legal mess is a red flag for investors because the heavily indebted drugmaker hasn’t earmarked enough liquidity to …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), and Endo International plc – Ordinary Shares (NASDAQ:ENDP) each beat expectations on Tuesday as …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) posted first quarter financial results yesterday for the year that might prove the once-sinking ship might have found …
Valeant Shows Signs of the Stabilization Valeant Pharmaceuticals Intl Inc (NYSE:VRX) investors are finally waking up from their nightmare, as the stock rockets 20% …
